EPC2

Across TCGA pan-cancer cohorts, EPC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPC2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher EPC2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EPC2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where EPC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	1.000	0.384	.020	5	view →
HNSC	DFS	Median	III,IV	0.894	1.000	.005	2	view →
GBM	OS	Tertile	All	0.536	0.317	.040	2	view →
LSCC	OS	Quartile	All	0.925	0.756	.027	1	view →
CCRCC	DFS	Median	All	1.000	0.931	.033	1	view →
PDAC	OS	Tertile	III,IV	0.990	0.724	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPC2–LUAD (DFS)

Open the LUAD breakdown →